Hospital-Treated Infections (Access to Novel Antibiotics: How Are Payers and Physicians Shaping the Market?) | Physician & Payer Forum | China | 2014
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and Asia-based biopharmaceutical companies are seizing this opportunity, such as TaiGen Biotechnology, which in May 2013 submitted an NDA for its innovative non-fluorinated quinonlone, Taigexyn, in China and Taiwan for treating community acquired pneumonia. In addition, AstraZeneca has started a Phase III trial for ceftazidime-avibactam (CAZ-AVI) combination therapy for complicated intra-abdominal infections and nosocomial pneumonia, and Bayer has acquired the exclusive rights to commercialize tedizolid in China, a second-generation oxazolidinone developed for treatment of Gram-positive infections. However, the Chinese government has been actively tackling abusive use of antibiotics through promulgation of administrative regulations for the clinical use of antimicrobials and the establishment of the National Antimicrobial Resistance Investigation Net to advocate rational use of antibiotics in hospital settings. This report analyzes how the different reimbursement and public health policies are shaping the antibiotics market in China.
